derralynn hughes

University College London

United Kingdom

Research Interests

Explore related searches

Professors in United Kingdom

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

Articles (10)

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Year:

2022

Collaborators (5)

Roser Torra

Profesor titular

University of Barcelona

SPAIN

View details

Csaba Siffel

University of Augsburg

UNITED STATES

View details

Matthew Gegg

University College London

UNITED KINGDOM

View details

Ulla Feldt-Rasmussen

Professor

University of Copenhagen

DENMARK

View details

Gustavo Maegawa

Assoc Prof

Columbia University

UNITED STATES

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

derralynn hughes

Research Interests

Explore related searches

Contact this professor

Articles (10)

Clinical Efficacy and Real-World Effectiveness of Fabry Disease Treatments: A Systematic Literature Review

Combined assessment of blood glucocerebrosidase activity and α-synuclein levels in GBA1 mutation carriers: A novel potential biomarker

Correction: Current and Emerging Therapies for Lysosomal Storage Disorders

Current and Emerging Therapies for Lysosomal Storage Disorders

Renal and multisystem effectiveness of 3.9 years of migalastat in a global real‐world cohort: Results from the followME Fabry Pathfinders registry

Changes in Angiogenesis and Bone Turnover Markers in Patients with Gaucher Disease Developing Osteonecrosis

Head-to-head trial of pegunigalsidase alfa versus agalsidase beta in patients with Fabry disease and deteriorating renal function: results from the 2-year randomised phase III BALANCE study

Long-term safety and efficacy of pegunigalsidase alfa: A multicenter 6-year study in adult patients with Fabry disease.

GALILEO-1: A Phase I/II Safety and Efficacy Study of FLT201 Gene Therapy for Gaucher Disease Type 1

Long-term multisystemic efficacy of migalastat on Fabry-associated clinical events, including renal, cardiac and cerebrovascular outcomes.

Collaborators (5)

Roser Torra

Csaba Siffel

Matthew Gegg

Ulla Feldt-Rasmussen

Gustavo Maegawa

Make your next move.